Kidney transplantation - New developments

Swiss Surgery

Volumn 9, Issue 5, 2003, Pages 205-212

  Dahm, F ^b   Weber, M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Kidney transplantation; Review

Indexed keywords

ALLOGRAFT; CADAVER DONOR; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; LIVING DONOR; MORBIDITY; MORTALITY; NEOPLASM; NEPHRECTOMY; PREOPERATIVE EVALUATION; RECURRENCE RISK; REVIEW; SURVIVAL; TISSUE ENGINEERING; XENOTRANSPLANTATION;

EID: 0141989869     PISSN: 10239332     EISSN: None     Source Type: Journal    
DOI: 10.1024/1023-9332.9.5.205     Document Type: Review

References (97)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341(23):1725-1730.
2. Meier-Kriesche HU, Ojo AO, Port FK et al. Survival improvement among patients with end-stage renal disease: Trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12(6):1293-1296.
3. Winkelmayer WC, Weinstein MC, Mittleman MA et al. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002; 22(5):417-430.
4. Swisstransplant. Jahresbericht 2002. Available from http://www.swisstransplant.org/DE/Files/publications/publications.html (accessed on 22.04.2003).
5. University Renal Research and Education Association; United Network for Organ Sharing. 2002 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001. Available from http://www.optn.org/data/annualReport.asp. (accessed on 15.06.2003).
6. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344(10):726-731.
7. Mange KC, Joffe MM, Feldman HI. Dialysis prior to living donor kidney transplantation and rates of acute rejection. Nephrol Dial Transplant 2003; 18(1):172-177.
8. European Best Practice Guidelines for Renal Transplantation (Section I: Evaluation, selection and preparation of the potential transplant recipient). Nephrol Dial Transplant 2000; 15(Suppl 7):3-38.
9. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347(4):284-287.
10. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75(4):425-429.
11. Breitenfeldt MK, Rasenack J, Berthold H et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16(2):130-136.
12. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997; 2(4)14-17.
13. Johnson DW, Herzig K, Purdie D et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000; 69(5):794-799.
14. Denton MD, Singh AK. Recurrent and de novo glomerulonephritis in the renal allograft. Semin Nephrol 2000; 20(2):164-175.
15. Brazda E, Ofner D, Riedmann B et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann Transplant 1996; 1(2):15-18.
16. Knispel HH, Klan R, Offermann G et al. Transplantation in autosomal dominant polycystic kidney disease without nephrectomy. Urol Int 1996; 56(2):75-78.
17. Glassman DT, Nipkow L, Bartlett ST et al. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urol 2000; 164(3 Pt 1):661-664.
18. Denton MD, Magee CC, Ovuworie C et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: A pathologic analysis. Kidney Int 2002; 61(6):2201-2209.
19. Matesanz R, Miranda B. A decade of continuous improvement in cadaveric organ donation: The Spanish model. J Nephrol 2002; 15(1):22-28.
20. Pessione F, Cohen S, Durand D et al. Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation 2003; 75(3):361-367.
21. Sola R, Guirado L, Diaz JM et al. Elderly donor kidney grafts into young recipients: Results at 5 years. Transplantation 2002; 73(10):1673-1675.
22. Kumar A, Verma BS, Srivastava A et al. Long-term follow-up of elderly donors in a live related renal transplant program. J Urol 2000; 163(6):1654-1658.
23. Schweizerische Akademie der Medizinischen Wissenschaften. Medizinisch-ethische Richtlinien zur Feststellung des Todes mit Bezug auf Organtransplantationen. Available from http://www.samw.ch/content/Richtlinien/d_DefTod.pdf (accessed on 17.05. 2003).
24. Brook NR, Waller JR, Nicholson ML. Nonheart-beating kidney donation: Current practice and future developments. Kidney Int 2003; 63(4):1516-1529.
25. Weber M, Dindo D, Demartines N et al. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002; 347(4): 248-255.
26. Nicholson ML, Metcalfe MS, White SA et al. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int 2000; 58(6):2585-2591.
27. Ratner LE, Ciseck LJ, Moore RG et al. Laparoscopic live donor nephrectomy. Transplantation 1995; 60(9):1047-1049.
28. Najarian JS, Chavers BM, McHugh LE et al. 20 years or more of follow-up of living kidney donors. Lancet 1992; 340(8823):807-810.
29. Goldfarb DA, Matin SF, Braun WE et al. Renal outcome 25 years after donor nephrectomy. J Urol 2001; 166(6):2043-2047.
30. Ellison MD, McBride MA, Taranto SE et al. Living kidney donors in need of kidney transplants: A report from the organ procurement and transplantation network. Transplantation 2002; 74(9): 1349-1351.
31. Yoshimura K, Ohara H, Ichioka K et al. Body image alteration after flank incision: Relationship between the results of objective evaluation using computerized tomography and patient perception. J Urol 2003; 169(1):182-185.
32. Duque JL, Loughlin KR, Kumar S. Morbidity of flank incision for renal donors. Urology 1999; 54(5):796-801.
33. Wolf JS Jr., Merion RM, Leichtman AB et al. Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy. Transplantation 2001; 72(2):284-290.
34. Schweitzer EJ, Wilson J, Jacobs S et al. Increased rates of donation with laparoscopic donor nephrectomy. Ann Surg 2000; 232(3): 392-400.
35. Pradel FG, Limcangco MR, Mullins CD et al. Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis 2003; 41(4):849-858.
36. Gershbein AB, Fuchs GJ. Hand-assisted and conventional laparoscopic live donor nephrectomy: A comparison of two contemporary techniques. J Endourol 2002; 16(7):509-513.
37. Dahm F, Weber M, Handschin AE et al. Laparoskopische hand-assistierte Nephrektomie zur Lebendnierenspende: die Methode der Wahl. Jahreskongress der Schweizerischen Gesellschaft für Chirurgie. Interlaken 2003.
38. Pace KT, Dyer SJ, Stewart RJ et al. Health-related quality of life after laparoscopic and open nephrectomy. Surg Endosc 2003; 17(1):143-152.
39. Erlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001; 14(4):347-356.
40. Opelz G, Wujciak T, Dohler B et al. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1(3):334-342.
41. Takemoto SK, Terasaki PI, Gjertson DW et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343(15):1078-1084.
42. Doxiadis, II, Smits JM, Schreuder GM et al. Association between specific HLA combinations and probability of kidney allograft loss: The taboo concept. Lancet 1996; 348(9031):850-853.
43. Kupiec-Weglinski JW. Graft rejection in sensitized recipients. Ann Transplant 1996; 1(1):34-40.
44. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280(14):735-739.
45. Mahoney RJ, Taranto S, Edwards E. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63(4):324-335.
46. Le Bas-Bernardet S, Hourmant M, Valentin N et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75(4):477-482.
47. Lich R Jr., Howerton LW, Davis LA. Recurrent urosepsis in children. J Urol 1961; 86:554.
48. Gregoir W, Van Regermorter G. Le reflux vesico-ureteral congenital. Urol Int 1964; 18:122.
49. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309(14):809-815.
50. Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. Lancet 1983; 2(8357):986-989.
51. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9):605-612.
52. Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360(9346):1662-1664.
53. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69(7):1252-1260.
54. Brinkmann V, Lynch KR. FTY720: Targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14(5):569-575.
55. Kahan BD. Sirolimus and FTY720: New approaches to transplant immunosuppression. Transplant Proc 2002; 34(7):2520-2522.
56. Hricik DE, O'Toole MA, Schulak JA et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis. J Am Soc Nephrol 1993; 4(6):1300-1305.
57. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68(12):1865-1874.
58. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. Cmaj 1992; 147(5):645-657.
59. Vanrenterghem Y, Lebranchu Y, Hene R et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70(9):1352-1359.
60. Hollander AA, Hene RJ, Hermans J et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study. J Am Soc Nephrol 1997; 8(2):294-301.
61. Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348(9028):643-648.
62. Grinyo JM, Gil-Vernet S, Seron D et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63(11):1688-1690.
63. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13(5):1365-1373.
64. Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11(10):1910-1917.
65. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 2001; 37(6):1162-1169.
66. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 2001; 12(4):828-833.
67. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72(6):1024-1032.
68. Opelz G, Dohler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72(7):1267-1273.
69. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 359(9308):741-746.
70. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing 'tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3):436-443.
71. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63(7):977-983.
72. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69(5): 834-841.
73. Ahsan N, Johnson C, Gonwa T et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years. Transplantation 2001; 72(2):245-250.
74. Jordan ML, Shapiro R, Vivas CA et al. FK506 «rescue» for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57(6):860-865.
75. Woodle ES, Cronin D, Newell KA et al. Tacrolimus therapy for refractory acute renal allograft rejection: Definition of the histologic response by protocol biopsies. Transplantation 1996; 62(7):906-910.
76. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345(8961):1321-1325.
77. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61(7):1029-1037.
78. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60(3):225-232.
79. Miller J, Mendez R, Pirsch JD et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69(5):875-880.
80. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67(3):411-415.
81. Adu D, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003; 326(7393):789.
82. Arend SM, Mallar MJ, Westendorp RJ et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12(8):1672-1679.
83. Herzog CA, Ma JZ, Collins AJ. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am J Kidney Dis 2000; 36(1):145-152.
84. Howard RJ, Patton PR, Reed AI et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73(12):1923-1928.
85. Hilbrands LB, Demacker PN, Hoitsma AJ et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5(12):2073-2081.
86. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000; 7(2):147-156.
87. Flechner SM, Avery RK, Fisher R et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66(12):1682-1688.
88. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340(19):1462-1470.
89. Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28(2):240-246.
90. Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347(7):488-496.
91. Carroll RP, Ramsay HM, Fryer AA et al. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41(3):676-683.
92. Loren AW, Porter DL, Stadtmauer EA et al. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003; 31(3):145-155.
93. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3(3):199-210.
94. Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74(10):1405-1409.
95. Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361(9368): 1502-1510.
96. Hammerman MR. Tissue engineering the kidney. Kidney Int 2003; 63(4):1195-1204.
97. Dooldeniya MD, Warrens AN. Xenotransplantation: Where are we today? J R Soc Med 2003; 96(3):111-7.